Telehealth & Digital Health

Establishment Labs has submitted its innovative Motiva implants for FDA approval in reconstruction, promising a new era for post-mastectomy care.

The cardiac device innovator adds seasoned sales and operations executives to prepare its novel cryoablation technology for the global market.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

With a former U.S. CTO, WHO expert, and life sciences vet, Welldoc is assembling a powerhouse team to dominate the AI-driven cardiometabolic care market.

An Indiana biotech prepares for biotech's biggest stage, showcasing a pipeline that offers new hope for chronic endocrine and metabolic disorders.

A new drug for a leading cause of blindness missed its primary goal, yet its unique ability to improve vision offers new hope for millions of patients.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

A new nonprofit telehealth platform for men is launching, but its true innovation may lie in its ambitious blend of holistic care and community support.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

Providence Care's new CEO is a former therapist. Can his clinical insight solve market challenges and deliver on a private equity growth plan?

The creator economy has mastered ROI-driven engagement. Can healthcare use its AI-powered playbook to improve patient outcomes and combat misinformation?

An Atlanta clinic's top award highlights a market shift toward minimally invasive fibroid treatment and a crucial fight for health equity in women's care.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.